CROI 2015 Program and Abstracts

Keyword Index

MaternalTB; 872 Maternal-to-infant transmission; 965 Mathematical model; 532, 675, 1105, 1106, 1112, 1117 Maturation; 42, 538, 539 Maturation inhibitor; 114LB MazF-T; 402 MBL2/APP; 462 mDC/monocyte; 388 MDR; 537

Monoclonal antibody; 50 Monocyte; 321, 279, 282, 283, 418, 684, 815 Monocyte activation; 466, 732, 738, 772 Montreal cognitive assessment; 472 Morbidity; 877, 1053 Mortality; 161, 316, 317, 577, 584, 641, 671, 720, 809, 810, 825, 831, 832, 833, 917, 990, 1049, 1081 Mother-to-child transmission (MTCT); 162, 868, 869, 872, 879, 893, 898, 904, 906 mtDNA; 496 Mucosa; 273 Mucosal • Barrier; 211 • Immunity; 168, 186, 267, 270, 272, 286, 289, 861 • Immunology; 262, 269, 287, 366 • Protection; 357 Multicohort study; 569 Multidrug resistance; 553 Multimorbidity; 764 Multiple risk groups; 1121 Multipurpose prevention technology; 1107 Mutation; 610 Mutation resistance; 564 Mycobacterium avium complex (MAC); 812 Mycobacterium tuberculosis; 309, 818, 819 Myeloid activation; 303Myeloid derived suppressor cells; 301 Myelotoxicity; 544 Myocardial infarction; 748, 749LB – N – NA-ACCORD; 996 Nadir CD4; 459, 706 Naive CD4T cell; 334 Naive patients; 611 NanoART; 529 Nanoformulated antiretroviral therapy (ATV+RTV); 543 Moxifloxacin; 95LB Mozambique; 873 MRI; 485, 488, 490 Mx1; 682 MxA; 296

Neuropsychological impairment; 448, 459, 467 Neuropsychology; 468, 488, 935 Neurosyphilis; 479, 840 Neurotoxicity; 478 Neutralization; 170LB, 346, 349, 903 Neutralization response; 343, 347 Neutralizing antibodies; 164LB, 345, 906 Neutralizing antibody; 590 Nevirapine; 36, 542 Nevirapine prophylaxis; 889, 909 Nevirapine resistance; 909 New antiretroviral; 104LB New oral HCV drugs; 16 Next-generation sequencing (NGS); 254, 255, 256, 257, 258, 593 NF-kappaB; 385 NFkB; 187 NFL; 474 NHANES; 789 NHBS; 850 Nigeria; 558, 1063 Nitric oxide; 500 NK; 372 NK cells; 52, 272, 277, 680 NK-likeT cells; 678 NK-pDC crosstalk; 285

Measles; 945, 946 Measurement; 976

Measures of HIV-1 persistence; 912 Mechanistically based equation; 863 Mediation; 1049 Medicaid; 1064, 1065 Medical monitoring project; 789 Medication sharing; 988 Medroxyprogesterone acetate; 858 Memory cells; 340, 530 Memory t cells; 382 MEMRI; 504

Men who have sex with men (MSM); 14, 22LB, 23LB, 73, 116, 241, 251, 252, 287, 671, 675, 713, 839, 841, 970, 972, 973, 977, 997, 1016, 1019LB, 1020, 1021, 1024, 1025, 1026, 1032, 1041, 1042, 1058, 1060, 1061, 1062, 1070, 1097, 1098, 1099, 1105, 1115 Menopause; 636 Menstrual cup; 857 Mental health disorders; 694 Mesoamerica; 242 Mesoamerican region; 601

NKG2D; 367 NKp46; 367 NKT cell; 278 Nondaily use; 978LB Non-Hodgkin lymphoma; 720 Nonnucleosides; 551

Metabolomics; 497, 498 Methamphetamine; 499 Metropolitan statistical area; 1040 MHC-1; 226, 363

Non-AIDS malignancy; 728 Non-AIDS mortality; 582, 729 Non–AIDS-defining cancers; 726 Non-B subtype; 201, 595 Non-classical monocytes; 466, 754, 796 Non-communicable diseases; 741

Microbial translocation; 271, 307, 310, 329, 477, 676 Microbicide; 26LB, 208, 287, 350, 963, 979, 993, 994 Microbiome; 897, 1085 Microbiota; 861, 266, 861 Microglial activation; 473, 477

Non-Hodgkin lymphoma; 725, 719, 725 Nonhuman primate neuroAIDS model; 503 Nonhuman primates; 962 Nonnucleoside reverse transcriptase inhibitor (NNRTI); 449, 510, 511, 566, 582, 930 Non-HAND; 471

Micronutrients; 567 MicroRNA; 471, 759

MicroRNA29; 296 Microvesicles; 366 Middle-income countries; 1118 Migration; 242, 1034 Minority-resistant variants; 983 Minority variants; 592, 982 miR-155; 385 Missed diagnosis; 33 Mitochondria; 411, 460, 500 Mitochondrial injury; 499 Mitochondrial toxicity; 785

Nanomedicine; 542 NAT screening; 1022

Nonhuman primate models; 591 Nonhuman primates; 223, 349 North America; 580, 996 Novel diagnostic tests; 621, 826 Novel drugs; 131 nPEP; 958, 958 NRTI; 537, 541, 585, 785, 788

Native-like envelope trimers; 164LB Natural killer cells; 367, 372, 679 Needle-exchange program; 1028 Nef; 189, 226, 227, 228 Negative Regulator; 388 Neisseria gonorrhoeae; 1026 Neopterin; 474 Network biology; 13 NeuroAIDS; 60, 62, 440, 447, 478, 504

NS5A inhibitor; 696 NS5A mutation; 696 Nuclease; 401 Nucleoside analog; 541 Nystatin; 844 – O – OAS; 682 Obesity; 763, 778 Observational cohort; 101, 569, 806, 865 Observational studies; 1025 Occult HBV in India; 704 Occupational; 1027 Occupational exposure; 957 OCT1; 519 Older female sex workers; 1030 Older population; 491

MIV-150; 967 MK-5172; 693

Neurocognition; 441, 447, 486 Neurocognitive; 57, 439, 936 • Disorders; 455 • Functioning; 450 • Impairment; 63, 451, 462, 469, 470, 483, 491, 499 • Performance; 442 Neurofilament light chain; 60

Mobile phone use; 559, 889 Mobile technology; 828LB MobileVMMC teams; 1086, 1086 Mobility; 1034 Modeling; 25, 150, 509, 531, 1116, 1119 Modified CD4T cells; 402 Molecular • Dynamics; 586 • Epidemiology; 92, 240, 241, 245, 246, 816LB • Mechanisms; 201

Keyword Index

Neuroimaging; 60, 447 Neuroimaging trait; 461 Neuroinflammation; 60, 477 Neurologic; 760 Neuronal injury; 481 Neuropathogenesis; 439, 469, 508 Neuropathy; 458 Neuropsychiatric tests; 60

• Modeling; 219 Monitoring; 828LB Monoamine; 498

688

CROI 2015